In vitro cultivation of human renal cell cancer

Williams, Richard D.; Elliott, Arthur Y.; Stein, Nell; Fraley, Elwin E.

doi:10.1007/bf02617972

Cited by 56 publications

(29 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the in vivo studies, the mouse osteosarcoma LM8 (23), human osteosarcoma SaOS2 (24), human fibrosarcoma HT1080 (25), human synovial sarcoma Syo-1 (26), human renal cancer 786-O (27), human prostate cancer PC-3 (28) and human lung cancer A549 (29) cell lines were used. LM8, SaOS2, Syo-1, 786-O, and A549 cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Nacalai Tesque, Inc., Kyoto, Japan) containing 10% fetal calf serum (FCS) (Nacalai Tesque, Inc.) and 100 U/ml penicillin G and 100 mg/ml streptomycin antibiotics (Nacalai Tesque, Inc.).…”

Section: Methodsmentioning

confidence: 99%

Cytotoxic effects of zoledronic acid-loaded hydroxyapatite and bone cement in malignant tumors

et al. 2017

View full text Add to dashboard Cite

Abstract. Metastatic and primary bone tumors are malignant tumors affecting the skeleton. Although the prognosis of patients with these tumors has improved with the development of effective chemotherapy, the challenges of local recurrence, subsequent osteolysis, degradation of bone strength and unresectable tumors persist. Local control of these tumors is therefore a key strategy to address these limitations. The third-generation bisphosphonate (BP), zoledronic acid (ZOL), has been demonstrated to reduce osteoclasts and exhibited potent antitumor effects in a number of malignancies. Hydroxyapatite (HA) and polymethyl methacrylate (PMMA) bone cement are used in orthopedic surgery as bone graft substitutes, for implant arthroplasty and bone strengthening, and as a sustained-release system for drugs such as antibiotics. At present, the antitumor effects of ZOL-loaded HA in vitro or in vivo or of ZOL-loaded bone cement in vivo have not been described. Therefore, the present study assessed the effects of ZOL-loaded HA and bone cement in malignant tumor cells. The two materials exerted strong antitumor effects against osteosarcoma, fibrosarcoma, synovial sarcoma, renal cancer, prostate cancer and lung cancer cells upon releasing ZOL. The antitumor effects of ZOL-loaded HA were less potent compared with those of ZOL-loaded bone cement, possibly as BPs exhibit higher affinity to HA. ZOL-loaded bone cement also exerted antitumor effects against pulmonary metastases and primary lesions, without exhibiting systemic toxicity in vivo. These results demonstrate that these materials may be beneficial for the treatment of malignant bone tumors, including metastatic bone tumors. In addition, as these materials are already in clinical use, such applications may be easily implemented.

show abstract

Section: Methodsmentioning

confidence: 99%

Cytotoxic effects of zoledronic acid-loaded hydroxyapatite and bone cement in malignant tumors

et al. 2017

View full text Add to dashboard Cite

show abstract

“…To generate standard curves for quantitative analysis of each gene, cell lines that were reliable and had verified sources of mRNA for the particular gene were chosen. Tissue RNA was extracted as described above, and total RNA for Axl and Gas6 standards was extracted from cultured RCC 786-O cells (32) and stable Gas6-transfected HEK293 cells (33), respectively, using CellDirect One-Step qRT-PCR kit (Invitrogen). A master mix of Taqman MGB primers and…”

Section: Methodsmentioning

confidence: 99%

Differential Expression of Axl and Gas6 in Renal Cell Carcinoma Reflecting Tumor Advancement and Survival

Gustafsson

Martuszewska

Johansson

et al. 2009

Clinical Cancer Research

135

129

View full text Add to dashboard Cite

Purpose: Overexpression of the receptor tyrosine kinase Axl is implicated in several cancers.Therefore, we conducted this study to determine the expression of Axl and its ligand Gas6 in various renal cell carcinoma (RCC) types and in oncocytoma. Experimental Design: Real-time quantitative reverse transcription-PCR was used to quantify tumor mRNA levels for Axl and Gas6 in a cohort (n = 221) of RCC patients. Serum levels of soluble sAxl and Gas6 proteins were measured using specific ELISA assays (n = 282). The presence of Axl protein in tumor tissue was evaluated by immunohistochemistry (n = 294). Results were correlated to tumor-associated variables, clinical biochemical tests, and patient survival. Results: Tumor Axl mRNA levels correlated independently to survival when assessed against tumor stage and grade. In the study group, the median cancer-specific survival of all RCC patients during 307 months of follow-up was 55 months (confidence interval, F40.4). The 25% of patients with lowest tumor Axl mRNA levels had significantly better survival than the rest (P = 0.0005), with 70% of the patients still alive at the end of follow-up. In contrast, in patients with medium-high Axl mRNA, only 25% were alive at the end of follow-up. Tumor Gas6 mRNA levels correlated to survival, tumor-associated variables, and disease severity as did serum levels of soluble sAxl and Gas6 protein. However, no correlation between Axl protein in tumor tissue and survival was found. Conclusions: Axl and Gas6 expression in RCC are associated with tumor advancement and patient survival. In particular, low tumorAxl mRNA levels independently correlated with improved survival.Renal cell carcinoma (RCC) represents f2% to 3% of all human cancers (1), being the most common cancer of the adult kidney (2). The prevalence is skewed between men and women (1.5:1), and RCC incidence peaks at 60 to 70 years of age (3). The only curative treatment of RCC is surgery (4). Today, smaller and less advanced RCC tumors are detected by imaging techniques, such as ultrasound and computed tomography, and nephron-sparing surgery of tumors <4 cm in diameter is an alternative that provides recurrence-free and long-term survival rates (5). However, the outcome of metastatic RCC is poor and mortality remains very high with a median cancer-specific survival of 21 months (6, 7). Treatment of metastatic RCC, in addition to removal of primary tumor and resection of metastases, is palliative and includes systemic therapies, such as immunotherapy (e.g., IFNa). Recently, a number of promising tyrosine kinase inhibitors are approved both in the United States and Europe for treatment of metastatic RCC (5).RCC is composed of different tumor types, including conventional or clear cell RCC (cRCC; representing the majority of RCCs, 75-85%), papillary RCC (pRCC; 10-15%), chromophobe RCC (chRCC; 4-5%), collecting duct carcinoma (<1%), and unclassified RCC (5%; ref. 8). In f4% to 5% of the cases, benign oncocytoma is diagnosed when RCC is suspected (9). The more aggressive ...

show abstract

“…The patient had a total serum calcium of 10.6-12.5 mg/dl, albumin 3.0 g/dl, and phosphorus 3.5 mg/dl. The culture methods and a complete characterization of the cell line have previously been published (3).…”

Section: Methodsmentioning

confidence: 99%

Human renal carcinoma cells produce hypercalcemia in the nude mouse and a novel protein recognized by parathyroid hormone receptors.

Strewler¹,

Williams²,

Nissenson³

1983

J. Clin. Invest.

173

View full text Add to dashboard Cite

In vitro cultivation of human renal cell cancer

Cited by 56 publications

References 9 publications

Cytotoxic effects of zoledronic acid-loaded hydroxyapatite and bone cement in malignant tumors

Cytotoxic effects of zoledronic acid-loaded hydroxyapatite and bone cement in malignant tumors

Differential Expression of Axl and Gas6 in Renal Cell Carcinoma Reflecting Tumor Advancement and Survival

Human renal carcinoma cells produce hypercalcemia in the nude mouse and a novel protein recognized by parathyroid hormone receptors.

Contact Info

Product

Resources

About